Protein arginine methylation/demethylation and cancer.
Protein arginine methylation/demethylation and cancer.
复制标题
DOI：
10.18632/oncotarget.11376
复制
发表时间：
2016-10-11
期刊：
影响因子：
--
通讯作者：
Le Romancer M
中科院分区：
文献类型：
--
作者：
Poulard C;Corbo L;Le Romancer M
蛋白质精氨酸甲基化是一种常见的翻译后修饰，涉及许多细胞过程，包括转录、DNA修复、mRNA剪接和信号转导。目前，蛋白质精氨酸甲基转移酶（PRMT）家族有9个已知成员，但只有一个精氨酸脱甲基酶已被确定，即Jumonji结构域包含6（JMJD6）。虽然其脱甲基酶活性最初受到质疑，但其作为精氨酸脱甲基酶和赖氨酸羟化酶的双重活性现在被认可。有趣的是，越来越多的精氨酸甲基化和去甲基化底物在肿瘤发生中起着关键作用。虽然这些酶的序列的改变尚未在癌症中确定，但它们的过表达与各种癌症有关，这表明它们可能构成治疗策略的靶点。本文就PRMTs和JMJD6在肿瘤发生中的作用作一综述。
Protein arginine methylation is a common post-translational modification involved in numerous cellular processes including transcription, DNA repair, mRNA splicing and signal transduction. Currently, there are nine known members of the protein arginine methyltransferase (PRMT) family, but only one arginine demethylase has been identified, namely the Jumonji domain-containing 6 (JMJD6). Although its demethylase activity was initially challenged, its dual activity as an arginine demethylase and a lysine hydroxylase is now recognized. Interestingly, a growing number of substrates for arginine methylation and demethylation play key roles in tumorigenesis. Though alterations in the sequence of these enzymes have not been identified in cancer, their overexpression is associated with various cancers, suggesting that they could constitute targets for therapeutic strategies. In this review, we present the recent knowledge of the involvement of PRMTs and JMJD6 in tumorigenesis.